RSV

2024 - 1 - 30

RSV Vaccine Updates and Impact on Public Health

Chuck Schumer - Dr. Jeffrey Kopin - GSK - respiratory syncytial virus - RSV vaccine

Learn about the latest developments in RSV vaccination, including vaccine effectiveness, shortages, and key figures involved in the fight against respiratory syncytial virus.

Respiratory syncytial virus (RSV) has become a critical concern for public health, especially affecting young infants and vulnerable individuals. Health experts have been evaluating the effectiveness of RSV vaccines during pregnancy to protect both mothers and infants. For over 60 years, efforts have been made to develop RSV vaccines to combat lower respiratory tract diseases in older adults. The recent shortage of the RSV vaccine in hospitals like Golisano Children's Hospital has raised alarm, prompting urgent federal actions called for by Senator Schumer. Clinical studies have highlighted the seriousness of RSV and influenza coinfections, emphasizing the need for preventive measures.

Senate Majority Leader Chuck Schumer has been advocating for fast-tracking the RSV vaccine to address the critical shortage faced by hospitals. Additionally, renowned figures like Dr. Jeffrey Kopin have been discussing the effectiveness of RSV vaccines and their impact on public health. Recent findings have unveiled the ability of RSV to trigger inflammation and nerve damage, shedding light on the complexities of the virus. Furthermore, research on gut bacterium and microbiota suggests potential protective factors against RSV and other respiratory viruses. Companies like GSK have reported significant sales of their RSV vaccines, indicating the market competition and the growing importance of vaccination against RSV.

In conclusion, the fight against RSV continues to evolve with ongoing research, advocacy for vaccination, and addressing shortages. Leaders in the medical field and pharmaceutical companies are at the forefront of the battle against respiratory syncytial virus, striving to improve public health outcomes and protect vulnerable populations.

Post cover
Image courtesy of "Medical News Today"

How effective is the RSV vaccine during pregnancy and how does it ... (Medical News Today)

Respiratory syncytial virus (RSV) affects all ages, including young infants. Health experts answer key questions about RSV vaccine for pregnant people and ...

Post cover
Image courtesy of "Scientific American"

For 60+ years, respiratory syncytial virus (RSV) vaccines have ... (Scientific American)

This year, healthcare providers have tools to help prevent lower respiratory tract disease caused by RSV for older adults. This podcast was funded by GSK ...

Post cover
Image courtesy of "WRVO Public Media"

Schumer urging federal action to combat shortage of RSV vaccine (WRVO Public Media)

Golisano Children's Hospital in Syracuse has only five doses of the RSV vaccine left. Other hospitals in the region have little to no vaccine supply.

Post cover
Image courtesy of "BMC Infectious Diseases"

Clinical features and outcomes of influenza and RSV coinfections: a ... (BMC Infectious Diseases)

Respiratory syncytial virus (RSV) and influenza are respiratory viral infections that can cause serious illness in vulnerable individuals, especially those with ...

PolitiFact - Social media post misleads about children's deaths in ... (PolitiFact)

A new drug to protect newborns and infants against respiratory syncytial virus, or RSV, has prompted concern on social m.

Post cover
Image courtesy of "LNP | LancasterOnline"

RSV vaccination is safe and offers peace of mind [commentary] (LNP | LancasterOnline)

This winter, in addition to the COVID-19 and flu vaccines, U.S. Food and Drug Administration-approved immunizations against respiratory syncytial virus ...

Post cover
Image courtesy of "fingerlakes1.com"

Schumer advocates for fast-tracking RSV vaccine amid shortage (fingerlakes1.com)

Senate Majority Leader Chuck Schumer visited Upstate University Hospital in Syracuse to address the critical shortage of the RSV (respiratory syncytial ...

Post cover
Image courtesy of "News-Medical.net"

Impact of nirsevimab immunization on pediatric RSV-related ... (News-Medical.net)

Respiratory syncytial virus (RSV) is one of the main reasons leading to hospitalization among young children worldwide and each year, an estimated 101000 ...

Post cover
Image courtesy of "WGN Radio"

Dr. Jeffrey Kopin: How effective is the RSV vaccine? (WGN Radio)

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about Elon Musk's Neuralink implanting ...

Post cover
Image courtesy of "Healthline"

RSV Can Trigger Inflammation and Nerve Damage (Healthline)

A new study has revealed that respiratory syncytial virus (RSV), the most common cause of lower respiratory tract infections, can infect nerve cells and ...

Post cover
Image courtesy of "Genetic Engineering & Biotechnology News"

Gut Bacterium Protective in Flu, RSV, SARS-CoV-2 Models (Genetic Engineering & Biotechnology News)

Authors hypothesize that gut microbiota composition broadly influences proneness to respiratory virus infection.

Post cover
Image courtesy of "Medical News Today"

Gut microbiota may influence may severity of COVID-19, RSV, and flu (Medical News Today)

A new mouse study suggests the presence of certain gut bacteria transforms alveolar macrophages into respiratory virus neutralizers.

Post cover
Image courtesy of "News-Medical.net"

Gut microbiome may hold key to fighting common respiratory viruses (News-Medical.net)

The composition of microbiota found in the gut influences how susceptible mice are to respiratory virus infections and the severity of these infections, ...

Gut microbiota influence severity of respiratory viral infection (Science Daily)

The composition of microbiota found in the gut influences how susceptible mice are to respiratory virus infections and the severity of these infections.

Post cover
Image courtesy of "FiercePharma"

GSK reports blockbuster sales for Arexvy in RSV race vs. Pfizer (FiercePharma)

GSK's RSV vaccine Arexvy generated $1.5 billion in sales in 2023, compared to $890 million for Pfizer's Abrysvo. But GSK says the market battle has just ...

Post cover
Image courtesy of "CNBC"

GSK posts blowout RSV vaccine sales, raises outlook as shots give ... (CNBC)

The RSV shot, called Arexvy, booked £1.2 billion, or $1.5 billion, in sales after only being on the market for roughly half a year.

GSK sales of RSV vaccine stay strong, beating forecast (BioPharma Dive)

Continued uptake of Arexvy in the U.S. pushed sales above $1.5 billion last year, outpacing those of Pfizer's rival shot Abrysvo. Published Jan. 31, 2024.

Post cover
Image courtesy of "pharmaphorum"

GSK on top in RSV jab rollout, but is Pfizer closing the gap? (pharmaphorum)

GSK's RSV vaccine Arexvy outsold Pfizer's Abrysvo last year, but fourth-quarter figures suggest the gap may be narrowing.

GSK's RSV vaccine Arexvy records £1.2B in sales in first year ... (Endpoints News)

GSK is looking to ride the momentum from its RSV vaccine sales into 2024 and beyond. Meanwhile, it has cut three infectious disease candidates from its ...

Post cover
Image courtesy of "Bloomberg"

GSK Lifts Long-Term Outlook, Buoyed by RSV Vaccine Sales (Bloomberg)

GSK Plc upgraded its long-term outlook, following the successful launch of its new RSV vaccine which soared past £1 billion ($1.27 billion) of sales only ...

Post cover
Image courtesy of "IDSA"

RSV Immunizations: A Crossover Episode with the Curbsiders and ... (IDSA)

Let's Talk ID is joining forces with the Curbsiders and the Cribsiders to discuss RSV immunizations! In this crossover episode, host Buddy Creech, MD, MPH, ...

Post cover
Image courtesy of "Barron's"

GSK's RSV Vaccine Is a Blockbuster After Just 4 Months. The Stock ... (Barron's)

's new respiratory syncytial virus vaccine hit blockbuster status in just four months, the company said Wednesday. The strong debut for Arexvy, the new vaccine, ...

Explore the last week